A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses

Trial Profile

A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses

Planning
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Girentuximab I-124 (Primary)
  • Indications Renal cell carcinoma
  • Focus Pharmacodynamics
  • Acronyms REDECT 2
  • Sponsors WILEX Inc
  • Most Recent Events

    • 16 Jan 2017 Status changed from withdrawn prior to enrolment to planning, as reported by a WILEX media release.
    • 16 Jan 2017 WILEX has been granted a special protocol assessment (SPA) from the FDA for this trial, as reported by a media release.
    • 14 Dec 2015 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top